NEUROCRINE BIOSCIENCES INC Insider Trading for January 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEUROCRINE BIOSCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NEUROCRINE BIOSCIENCES INC for January 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | M | 41.78 | 300 | 12,534 | 56,223 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | M | 41.78 | 3,477 | 145,269 | 56,523 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.00 | 100 | 12,000 | 15,705 | 15.8 K to 15.7 K (-0.63 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.00 | 300 | 36,000 | 15,805 | 16.1 K to 15.8 K (-1.86 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Buy | M | 41.78 | 300 | 12,534 | 16,105 | 15.8 K to 16.1 K (+1.90 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.03 | 1,600 | 192,044 | 15,805 | 17.4 K to 15.8 K (-9.19 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.03 | 3,477 | 417,327 | 17,405 | 20.9 K to 17.4 K (-16.65 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Buy | M | 41.78 | 3,477 | 145,269 | 20,882 | 17.4 K to 20.9 K (+19.98 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 120.00 | 400 | 48,000 | 223,697 | 224.1 K to 223.7 K (-0.18 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 120.03 | 1,600 | 192,047 | 224,097 | 225.7 K to 224.1 K (-0.71 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 35.99 | 1,100 | 39,589 | 23,233 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 32.99 | 8,958 | 295,524 | 0 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 35.99 | 8,612 | 309,946 | 24,333 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.98 | 600 | 71,985 | 29,002 | 29.6 K to 29 K (-2.03 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 600 | 21,594 | 29,602 | 29 K to 29.6 K (+2.07 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.96 | 500 | 59,980 | 29,002 | 29.5 K to 29 K (-1.69 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 500 | 17,995 | 29,502 | 29 K to 29.5 K (+1.72 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.95 | 8,958 | 1,074,512 | 29,002 | 38 K to 29 K (-23.60 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 32.99 | 8,958 | 295,524 | 37,960 | 29 K to 38 K (+30.89 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.98 | 4,601 | 552,041 | 29,002 | 33.6 K to 29 K (-13.69 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 4,601 | 165,590 | 33,603 | 29 K to 33.6 K (+15.86 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.99 | 4,011 | 481,259 | 29,002 | 33 K to 29 K (-12.15 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 4,011 | 144,356 | 33,013 | 29 K to 33 K (+13.83 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | ROBERTS EIRY | Chief Medical Offic ... | Sell | S | 111.06 | 2,632 | 292,297 | 15,845 | 18.5 K to 15.8 K (-14.24 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.65 | 164,801 | 1,425,529 | 0 | |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 143,449 | 1,242,268 | 0 | |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 110.22 | 164,801 | 18,164,778 | 441,071 | 605.9 K to 441.1 K (-27.20 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.65 | 164,801 | 1,425,529 | 605,872 | 441.1 K to 605.9 K (+37.36 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 110.21 | 143,449 | 15,809,098 | 441,071 | 584.5 K to 441.1 K (-24.54 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 143,449 | 1,242,268 | 584,520 | 441.1 K to 584.5 K (+32.52 %) |